Product Description

Crizotinib is an orally administered aminopyridine inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and c-Met/hepatocyte growth factor receptor (HGFR) with antitumor activity. Crizotinib binds to and inhibits ALK kinase and ALK fusion protein in an ATP-competitive manner. In addition, crizotinib inhibits c-Met kinase and disrupts the c-Met signaling pathway. Overall, this agent inhibits the growth of tumor cells.ALK belongs to the insulin receptor superfamily and plays an important role in the development of the nervous system.ALK dysregulation and gene rearrangements are associated with a range of tumors.